George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- March15 2003
- Volume 10
- Issue 5
BUCS' VICTORY A PLUS?
Author(s)Michael Sheehan
Advertisement
If you put any faith in the SuperBowl theory, the 48-21 win by theTampa Bay Buccaneers in Januaryshould give you some hope. Orshould it? The Super Bowl indicatorsays if an NFC team or one fromthe original NFL wins, stocks willbe up by the end of the year. If theAFC team wins, stocks are headeddown. At one point, the indicatorhad a blistering 90% accuracy rate,but getting it wrong in 4 of the past5 years has dropped its batting averageto 80.5%. But don't bet thefarm on an up stock market yet,some pessimistic prognosticatorssay. The Bucs started as an AFCteam in 1976 before moving to theNFC the following year, whichmeans that stocks may be headedfor a 4th straight losing season.
Articles in this issue
about 18 years ago
Know the Seven Sins of Practice Marketingabout 18 years ago
Don't Take Your Listing for Grantedabout 18 years ago
Offer an Easier Cholesterol Testabout 18 years ago
The FTC Helps Disconnect Telemarketersabout 18 years ago
Proposed Tax Package Divides Investorsabout 18 years ago
Taxes and Spendingabout 18 years ago
Space Shuttle Doctors Rememberedabout 18 years ago
Hail Columbiaabout 18 years ago
Will Your Savings Be Decimated by LTC?about 18 years ago
BEATING BROKER FEESAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5